Research Program Payments. In consideration for Merus’ performance of its obligations under the Research Program, and subject to the terms contained in this Agreement, Ono shall provide the FTE funding as provided for in Section 6.2.
Research Program Payments. Celanese agrees to pay to Symyx Research Expenses for the conduct of the Research Program, in a total not less than the Field Minimum Funding for all Active Fields. At a minimum, Celanese shall fund the conduct of the Research Program for a minimum of three (3) years in the aggregate amount of eleven million four hundred and fifty thousand dollars ($11.45 million), and may provide funding for further years, subject to the terms and conditions herein. All funds are to be used for the Research Program as budgeted by the applicable RFC.
Research Program Payments. Each Party will pay the other Party for the costs and expenses as set forth in each Research Plan, provided that Pfizer will bear the costs associated with Research Plan Services performed by Cellectis related to Pfizer Targets, as set forth in the Research Plan, at the FTE Rate. During the Research Term, Pfizer will provide [***] Pfizer FTEs [***] for Research Plan Services related to Cellectis Program Targets utilizing Pfizer infrastructure and technology as set forth in the Research Plan. Subject to the foregoing, the JRC shall determine the specific number of FTEs that shall perform Research Plan Services for Cellectis from time to time. Notwithstanding the foregoing, Pfizer shall only be obligated to reimburse Cellectis for the number of FTEs actually incurred and reported pursuant to Section 5.2.3 in the performance of its Research Plan Services.
Research Program Payments. (a) Novartis or its Affiliates shall make a one-time, non-refundable up-front payment of [***] US Dollars (US$[***]) for Research Program One within sixty (60) calendar days after the receipt by Novartis of Evotec’s Invoice for the same, which Invoice may be sent after the Effective Date of this Agreement. Such up-front payment shall constitute consideration for access to Evotec Intellectual Property during the first three (3) years of the Collaboration Period. For clarity, access to Evotec Intellectual Property during the Collaboration Period after the first three (3) years will be provided free of charge. For further clarity, this up-front payment shall be made only once for Research Program One, regardless of the number of Research Plans or Targets pursued under Research Program One, and shall not be made for Research Program Two.
(b) Novartis shall make research payments to Evotec in connection with each Research Program equal to [***] US Dollars (US$[***]) per FTE assigned to such Research Program per year. Such payments shall be (i) made quarterly (based, for Research Program One, on the Effective Date, and, for Research Program Two, on the Commencement Date of Research Program Two) in arrears, (ii) based on the actual number of FTEs assigned to such Research Program during the preceding quarter and (iii) paid within sixty (60) calendar days after the receipt by Novartis of Evotec’s Invoice for the same. The total payments to Evotec for FTEs assigned to each Research Program shall not exceed [***] US Dollars (US$[***]) per year for the Collaboration Period. At no time during the Collaboration Period shall more than two (2) FTEs out of the total number of FTEs assigned to each Research Program be devoted to managerial activities. Evotec is entitled to limit the number of FTEs assigned to each Research Program based on the funding levels set forth above. For the purpose of clarity, but subject to 5.1 (c), standard reagents, consumables and travel are included in the research funding set forth above.
(c) Evotec may use Third Parties to generate specialty reagents or to conduct research in connection with the Research Collaboration, subject to Novartis’ prior written approval, and provided that all such Third Parties agree in writing (i) that all intellectual property generated by such Third Party during the course of such research shall be deemed to be Project Intellectual Property, (ii) to take all steps required under all applicable law(s) relating to...
Research Program Payments. 6.2.1 [******]
Research Program Payments. In consideration for OntoChem’s performance of its activities under the Research Plan, Anixa will:
(a) pay OntoChem 100,002 Euros in six (6) equal installments as follows: (i) 16,667 Euros within five (5) days after the Effective Date; and (ii) five (5) installments in the amount of 16,667 Euros on each one-month anniversary of the Effective Date, except that the last such payment will be due within thirty (30) days after completion of all activities under the Research Plan; and
(b) reimburse OntoChem for its out-of-pocket expenses incurred in performing the Research Plan on a pass-through basis without xxxx-up, within thirty (30) days after delivery of an invoice therefore (including reasonable supporting documentation), provided that Anixa has approved such expenses in advance and in writing (including in regard to the selection of specific Hit Compounds to be synthesized and analyzed in biological assays). It is estimated that OntoChem’s out-of-pocket expenses under the Research Plan will include 110,000 Euros payable to Tube Pharmaceuticals GmbH as a subcontractor of OntoChem, subject to Section 2.5.
(c) High-throughput screening compounds OntoChem will forward a commercial proposal to acquire these compounds at the sole discretion of Anixa. Both parties will agree on payment conditions.
(d) Extra custom synthesis OntoChem will forward a commercial proposal to have synthesized these compounds at the sole discretion of Anixa. Both parties will agree on payment conditions.
(e) Biological testing OntoChem will forward a commercial proposal to have biologically test these compounds at the sole discretion of Anixa. Both parties will agree on payment conditions.
Research Program Payments. In addition to the payments pursuant to Sections 3.1 and 3.2 above, Novartis shall make the following payments to Hybridon in connection with the Research Program. Each payment shall be made within [**] days of Novartis' receipt of the related Hybridon Invoice.
Research Program Payments. Organon agrees to pay to Pharmacopeia research funding during the Research Program Term, in the following amounts (unless changed pursuant to Section 2.4 hereof): PERIOD AMOUNT ------------------------- ------ Year 1 [***] Year 2 [***] Year 3 [***] Total Research Payments [***] [*** Confidential Treatment Granted]
Research Program Payments. 10 2.4 Research Program Milestones and Payments...........................................................11 2.5
Research Program Payments. During the Research Program, ABBOTT shall be responsible for SPECTRx's actual costs for the cost categories set forth in Appendix 2.3 incurred for completion of tasks under Phases 1a and 1b of the Research Program as set forth in the Research Program Plan. Such payments shall be made in accordance with the quarterly budget as approved by the Research Committee in accordance with Section 2.1 and shall be paid to SPECTRx in advance of such quarter. Any budget revisions or variance shall be subject to the review and approval of the Research Committee. Any funds not expended by SPECTRx in one quarter shall be credited to the subsequent quarter. If SPECTRx receives notification of termination of this Agreement from ABBOTT or delivers such notice to ABBOTT in accordance with Section 10.2 prior to the completion of the Research Program, then SPECTRx shall immediately commence a wind down in good faith of its research tasks under the Research Program Plan, shall immediately terminate or notice termination, as permitted, of any obligations which incur costs under the Research Program Plan, shall not enter into any new financial commitments regarding the Research Program and shall take all reasonable steps to minimize any existing and/or continuing costs under the Research Program Plan which cannot be immediately terminated. SPECTRx shall reimburse ABBOTT for all advance payments made to SPECTRx which are in excess of the actual costs of the Research Program as of the date of termination less any contractual obligations of the Research Program which by their terms are noncancelable and thus extend beyond the termination date and other similar costs which cannot be reasonably avoided.
